Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

(2010) Ilke Sipahi et al.   LANCET ONCOLOGY

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials

(2009) Craig I Coleman et al.   JOURNAL OF HYPERTENSION

Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor

(2009) D. R. Soto-Pantoja et al.   MOLECULAR CANCER THERAPEUTICS

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist

(2009) D. R. Rhodes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

(2008)   LANCET

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

(2008) Nish Chaturvedi et al.   LANCET

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

(2008) Anne Katrin Sjølie et al.   LANCET

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

(2008) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

(2008) Barry M. Massie et al.   NEW ENGLAND JOURNAL OF MEDICINE